Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Begel

Psychiatry Santa Monica, CA Medical Doctor

NPI 1376609149 CMS profile 198708

1247 7Th St Ste 100, Santa Monica, CA 90401

Open in the dashboard

General payments

$5,235

184 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Begel of Santa Monica, CA is reported in the CMS Open Payments database as having received $5,235 across 184 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $809 26
2024 General $512 18
2023 General $698 26
2022 General $1,444 50
2021 General $570 21
2020 General $207 10
2019 General $996 33

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Begel
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Daniel Begel were reported at $809. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Daniel Begel Psychiatry median Middle half National median
2019 $996 $184 $59–$605 $163
2020 $207 $119 $36–$372 $114
2021 $570 $143 $43–$576 $132
2022 $1,444 $153 $50–$590 $149
2023 $698 $170 $56–$651 $160
2024 $512 $179 $57–$673 $164
2025 $809 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Otsuka America Pharmaceutical, Inc. $1,474 42 payments
  2. Alkermes, Inc. $1,124 41 payments
  3. Neurocrine Biosciences, Inc. $611 19 payments
  4. ITI, Inc. $553 20 payments
  5. Janssen Pharmaceuticals, Inc $542 15 payments
  6. Sunovion Pharmaceuticals Inc. $256 19 payments
  7. Teva Pharmaceuticals USA, Inc. $229 9 payments
  8. Lundbeck LLC $170 7 payments
  9. E.R. Squibb & Sons, L.L.C. $85 3 payments
  10. AbbVie, Inc. $80 4 payments
  11. Other $111 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,161 182 payments
  2. Education $74 2 payments
Products named General payments · program years 2019–2025
  1. REXULTI $970 29 payments
  2. ABILIFY MAINTENA $833 27 payments
  3. LYBALVI Cns $719 26 payments
  4. ARISTADA Cns $719 27 payments
  5. ARISTADA Cns $719 27 payments
  6. ARISTADA Cns $589 21 payments
  7. ARISTADA Cns $589 21 payments
  8. CAPLYTA $498 18 payments
  9. INGREZZA $426 15 payments
  10. LYBALVI Cns $392 14 payments
  11. Other $2,786 106 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

372

Median for Psychiatry: 574

Drug cost

$133,240

Median for Psychiatry: $27,624

Branded share of claims

37.1%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Invega Sustenna Paliperidone Palmitate Brand 30 $75,425
Abilify Maintena Aripiprazole Brand 21 $52,368
Carbamazepine Er Carbamazepine Brand 26 $1,840
Oxcarbazepine Generic 38 $1,142
Ziprasidone Hcl Generic 20 $689
Lurasidone Hcl Generic 16 $281
Aripiprazole Generic 28 $271
Bupropion Xl Bupropion Hcl Brand 30 $254
Quetiapine Fumarate Generic 25 $230
Benztropine Mesylate Generic 17 $188

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$5,368

Medicare's payments for the services billed

Medicare patients

15

Average age 48

Services billed

57

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Ischemic heart disease 0%
Atrial fibrillation 0%
Cancer 0%
Osteoporosis 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LYBALVI
  • Alkermes, Inc. $120
$120 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $94
  • Lundbeck LLC $24
$118 — —
ARISTADA
  • Alkermes, Inc. $84
$84 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $59
$59 — —
COBENFY
  • E.R. Squibb & Sons, L.L.C. $27
$27 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

184 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record